| 產(chǎn)品編號 | bsm-61591R |
| 英文名稱 | Dynamin 2 Recombinant Rabbit mAb |
| 中文名稱 | 酶動力蛋白2重組兔單抗 |
| 別 名 | CMT2M; CMTDI1; CMTDIB; DI CMTB; Dnm2; DYN II; DYN2; Dynamin II; Dynamin2; DynaminII; DYNII. |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | |
| 交叉反應(yīng) | Human,Mouse,Rat |
| 產(chǎn)品應(yīng)用 | WB=1:1000-1:2000,IHC-P=1:100-1:200,IHC-F=1:100-1:200,IF=1:50-1:200,Flow-Cyt=1:20-1:100,ICC/IF=1:50-1:200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 98 kDa |
| 檢測分子量 | 98 |
| 性 狀 | Liquid |
| 免 疫 原 | A synthesized peptide derived from human Dynamin 2: 750-800/870 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol. |
| 保存條件 | Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton.Plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macropinocytosis. SWISS: P50570 Gene ID: 1785 發(fā)動蛋白是一種胞質(zhì)溶膠蛋白, 又稱：酶動力蛋白。 能夠同GTP結(jié)合并將GTP水解。 發(fā)動蛋白2(Dynamin 2)是大的鳥苷三磷酸酶（GTPases）和eNOS存在相同的膜區(qū)室。研究顯示Dynamin 2能與eNOS直接作用增強(qiáng)eNOS的活性。Dynamin 2參與Caveolae 的內(nèi)陷活動、小囊的形成與運(yùn)輸以及受體介導(dǎo)的胞吞作用。 Dynamin 2能和牛主動脈的內(nèi)皮細(xì)胞溶菌產(chǎn)物的eNOS免疫共沉淀。Ca2+轉(zhuǎn)運(yùn)體刺激的的內(nèi)皮細(xì)胞增強(qiáng)了發(fā)動蛋白免疫共沉淀作用，說明蛋白間的相互作用能夠被細(xì)胞內(nèi)的ca2 |
| 產(chǎn)品圖片 |
Western blot analysis of Jurkat cell lysate. Using Dynamin 2 (bsm-61591R) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
